

Erratum: Interfering amino terminal peptides and functional implications for heteromeric gap junction formation

Eric C. Beyer¹, Xianming Lin² and Richard D. Veenstra²*

¹ Department of Pediatrics, University of Chicago, Chicago, IL, USA

² Department of Pharmacology, SUNY Upstate Medical University, Syracuse, NY, USA

*Correspondence: veenstrr@upstate.edu

Edited by:

Harry Fozzard, The University of Chicago, USA

A commentary on

Interfering amino terminal peptides and functional implications for heteromeric gap junction formation

by Beyer, E. C., Lin, X., and Veenstra, R. D. (2013). Front. Pharmacol. 4:67. doi: 10.3389/fphar.2013.00067 There was an inadvertent error in **Figure 4**, panel (**F**), pertaining to the effect of the iNT-Cx50a peptide on the spermine block of rat Cx40 gap junctions. The data that originally appeared in this figure was the same data plotted in **Figure 4**, panel (**B**) for the iNT-Cx40b peptide. The data in **Figure 4B** is correct and the correct data for the iNT-Cx50a (n = 4) is now illustrated in this revised version of **Figure 4** for the original manuscript. The corresponding author regrets the error that occurred while configuring the figures for this manuscript and accepts sole responsibility for this mistake. The iNT-Cx50a peptide




FIGURE 4 | (A) The sensitivity of four connexin-specific gap junctions was tested using the 2 mM spermine block assay. Human Cx40 (hCx40, ■) displayed similar V_i-dependent sensitivity to spermine as rCx40 despite the N9 substitution. Cx37 (o), Cx46 (o), and Cx50 (o) gap junctions were all ≥60% inhibited by spermine. The maximum inhibition of Cx37 gi occurred at +20 mV, half the Vi required for maximal block of any other known connexin-specific gap junction. (B) The ability of iNT-Cx40 peptides to interfere with spermine block was tested by adding 500 µM spermine and iNT-Cx40a or iNT-Cx40b peptides to one patch pipette. The carboxyl-terminal hydroxylated (-OH, z = -4) form of the Cx40 peptide (Cx40b) effectively abolished the Vi-dependent spermine block, while the amidated form (Cx40a, $-NH_2$, z = -3) was only partially effective (ANOVA, f-value < 0.05). (C) ΔI_2 current traces from an rCx40 cell pair with $500 \mu M$ spermine added to cell 1. I_i decreased during the positive 30, 40, and 50 mV V_i pulses and returned to prepulse levels during subsequent

negative V_i pulses, This illustrates the time- and V_i-dependent spermine block and unblock of rCx40 gap junctions. (D) 12 current traces from an rCx40 cell pair experiment with $500\,\mu\text{M}$ spermine and the iNT-Cx40b peptide added to cell 1. Accounting for the occurrence of Vi-dependent gating at $V_i > \pm 40 \text{ mV}$, instantaneous and steady state I_2 increased in a stepwise (ohmic) fashion with increasing Vi amplitude, indicative of a lack of spermine block. (E) A negatively charged (z = -4) iNT-Cx50b peptide failed to significantly prevent the 500 µM spermine block of rCx40 gap junctions, suggesting that the bimolecular interactions between the rCx40 NT domain, spermine, and iNT peptides are not purely based on electrostatic forces. (F) An iNT-Cx50a peptide [based on amino acids 9-13 and possessing a carboxyl-terminal valence (z) of -3] significantly reduced the 500 μ M spermine block of rCx40 gap junctions, suggesting a structural requirement for the interactions of iNT-Cx peptides with NT domains or spermine molecules.

was 95% effective in preventing the inhibition of Cx40 gap junctions by 500 microM spermine and inclusion of the correct data for the iNT-Cx50a peptide does not alter the results or conclusion of the original manuscript, just the accuracy of reporting the experimental data. The legend for **Figure 4** is not affected in any way and is reproduced here in its entirety.

Received: 26 June 2013; accepted: 04 July 2013; published online: 23 July 2013.

Citation: Beyer EC, Lin X and Veenstra RD (2013) Erratum: Interfering amino terminal peptides and functional implications for heteromeric gap junction formation. Front. Pharmacol. **4**:94. doi: 10.3389/fphar. 2013.00094 This article was submitted to Frontiers in Pharmacology of Ion Channels and Channelopathies, a specialty of Frontiers in Pharmacology.

Copyright © 2013 Beyer, Lin and Veenstra. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.